Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960599 | 0.82 | F7 (0.45) | — | |
| SCHEMBL4960568 | 0.79 | HPGD (0.54) | RAB9ANPC1SMN1; SMN2POLBKMT2A | |
| SCHEMBL5154948 | 0.77 | ST14 (0.44) | RAB9ANPC1SMN1; SMN2POLBHPGD | |
| SCHEMBL4961414 | 0.76 | F7 (0.67) | NPC1POLB | |
| SCHEMBL4958068 | 0.76 | F7 (0.48) | — | |
| SCHEMBL4959678 | 0.75 | ALDH1A1 (0.43) | SMN1; SMN2POLBKMT2AHPGDMEN1 | |
| SCHEMBL4959775 | 0.73 | F7 (0.66) | — | |
| SCHEMBL14590051 | 0.70 | SMN1; SMN2 (0.65) | RAB9ANPC1SMN1; SMN2ALOX15POLB | |
| SCHEMBL1303744 | 0.69 | SMN1; SMN2 (0.69) | RAB9ANPC1SMN1; SMN2ALOX15POLB | |
| SCHEMBL358181 | 0.69 | SMN1; SMN2 (0.62) | RAB9ANPC1SMN1; SMN2ALOX15POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312161-A1 | Compounds For Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISK HEALTH CARE AG (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20080312161-A1 | Compounds For Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISK HEALTH CARE AG (CH) | 2008-12-18 | — | — | US | disclosed |
| US-20080312161-A1 | Compounds For Stabilizing Factor VII Polypeptide Formulations | NOVO NORDISK HEALTH CARE AG (CH) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312161-A1 | Compounds For Stabilizing Factor VII Polypeptide Formulations | F7, F5, F13B | RAB9A 1217/4885NPC1 1908/4885SMN1; SMN2 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.